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Abstract
START-Register – Survey on anTicoagulated pAtients RegisTer – is an independent, incep-
tion-cohort, observational, collaborative database aimed at recording prospectively the clini-
cal history of adult patients starting anticoagulant treatment for any reason and using
whatever drug. In this article we present the START-Register and give cross section base-
line data focusing on non valvular atrial fibrillation (NVAF). Participants are asked to insert
prospectively consecutive patients recorded as electronic file on the web-site of the registry.
Required data are: demographic and clinical characteristics of patients, associated risk fac-
tors for stroke and bleeding, laboratory routine data, clinical indication for treatment, ex-
pected therapeutic range (in cases of treatment with vitamin K antagonists -VKAs). The
follow-up is carried out to record: quality of treatment (for patients on VKAs), bleeding com-
plications, thrombotic events, and the onset of any type of associated disease. To date
5252 patients have been enrolled; 97.6% were on VKAs because direct oral anticoagulants
(DOAC) have been available in Italy only recently. The median age was 74 years [interquar-
tile range (IQR) 64-80]; males 53.7%. This analysis is focused on the 3209 (61.1%) NVAF
patients. Mean CHADS2 score was 2.1±1.1, CHADSVASc score was 3.1±1.3;median age
was 76 years (IQR 70-81); 168 patients (5.3%) had severe renal failure [Creatinine clear-
ance (CrCl) <30 ml/min]. Moderate renal failure (CrCl 30-59 ml/min) was found in 1265 pa-
tients (39.5%). The analysis of the START-Register data shows that two-third of patients
who started chronic anticoagulant treatment had NVAF, one-third of them was > 80 years
with high prevalence of renal failure.
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Introduction
Oral anticoagulation treatment with vitamin K antagonist (VKA) has been shown to be effec-
tive in numerous randomized clinical trials[1], but despite the potential clinical benefits they
are underused especially in patients at high risk of bleeding [2]. In the last few years a good
deal of effort has been directed towards the development of novel direct oral anticoagulants
(DOAC) in order to avoid the difficulties and risks associated with VKA therapy. Several phase
III, non-inferiority, large trials in patients with non-valvular atrial fibrillation (NVAF)[3–6],
and studies of acute[7–11]or extended [12,13] treatment in patients with venous thromboem-
bolism (VTE) have recently been published investigating the efficacy and safety of 4 different
DOAC (dabigatran, rivaroxaban, apixaban and edoxaban) versus standard anticoagulation (in
most cases VKAs) for preventing thromboembolic complications in these clinical conditions.
In clinical trials however patients are usually carefully selected and there is very close control,
factors that may probably result in lower rates of complications and therapeutic failure. This
makes it difficult not only to assess the possible value and risk of DOAC in everyday clinical
practice, but also to evaluate their health-economic benefits.
Observational studies offer information on clinical routine practice, and could highlight
emerging issues. In 2011 we proposed the implementation of a collaborative database to pro-
spectively record the clinical history of patients starting anticoagulant treatment for any reason
and whatever the drug used. The study, called START-Register—Survey on anTicoagulated
pAtients RegisTer—is designed to provide: a) information on the effects of available anticoagu-
lant treatments, improving the knowledge of epidemiologic, diagnostic, and clinical features of
thrombotic diseases; b) to enhance our understanding of the risk-benefits of the various antico-
agulant drugs and therapy options. In this article we present the START-Register and its de-
sign, and give a cross section of baseline data collected at the moment, in particular focusing on
included patients with NVAF.
Material and Methods
START-Register design
The START-Register is an observational, multicenter, dynamic cohort study that includes adults
(18 years) who start anticoagulation therapy, whatever the drug and dosage used. More recently
a branch of the registry also included patients treated with antithrombotic drugs, especially new
antiplatelet drugs (START-Antiplatelet); the present article reports only on the anticoagulation
branch of the registry. The aim of the START-Register is to collect data on the incidence of ad-
verse events in patients taking anticoagulant, as well of determinants of them and quality of life or
patient compliance to treatment. The study design and protocol has been drafted and approved
by the Executive Committee that manages the START-Register. The Executive Committee de-
signed a Coordinating Member (G.P.), who first obtained authorization to set up the registry
from the Ethical Committee of his Institution (Azienda Ospedaliero-Universitaria, Policlinico S.
Orsola-Malpighi, Bologna, Italy) on October 2011 (N = 142/2010/0/0ss") (NCT02219984). The
same institution was entrusted to deploy and maintain the registry central database. The STAR-
T-Register sets itself an indefinite time limit and is an entirely independent project. Public and
private institutions, companies and individuals interested in the issue of anticoagulant treatment
(manufacturers of drugs or other goods and services) are asked by the Executive Committee to
help funding the registry via unrestricted grants without any right to access database data. Mem-
bers of the Executive Committee do not receive any payment or fee for their work.
The registry is open to all physicians (called Participants) prescribing anticoagulant therapy
and who agree to the Registry protocol. Participants should obtain approval from their local
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Institution Review Board. Participants are required to enter patients’ data only after obtaining
a written informed consent from the patient. Participants can propose specific studies based on
Registry data and have access to pertinent data after acceptance by the Executive Committee.
Enrolment of at least 20 patients per year is required to be granted access to study data or pro-
pose collaborative studies.
START-Register procedures
Patient eligibility. Patients18 years who at the time of inclusion have been receiving
anticoagulation therapy for no more than 30 days are eligible. The Registry aims at following
patients especially during the first 12 months of treatment, though a long-term follow-up is
recommended for patients who receive an indefinite anticoagulation. Therefore, patients with
life-expectancy<6 months, or not residents in the Participant region, or planning leaving in
the next 6 months are not eligible, as well as patients already enrolled in phase II or III clinical
studies. Patients enrolled in other observational or phase IV studies can be included in the
START-Register.
Follow-up of enrolled patients is mandatory for at least one year. Therefore, participants are
required to provide data of all significant events occurring in enrolled patients for at least 12
months, including death, bleeding or thrombotic complications, and development of major
organ failure even if use of anticoagulants has been interrupted before 12 months. Participants
are required to enrol their patients consecutively, without any a-priori exclusion criteria other
than life-expectancy or geographical inaccessibility. Definition of the time-framing for enrol-
ment (e.g., one week every month, or the first month of the year) is left at each participant’s dis-
cretion, as long as it provides a random enrolment of patients. Between-participants difference
in enrolled patients is anticipated, since some participants may be following patients having
preferentially a disease (e.g., atrial fibrillation) or receiving only a particular anticoagulant
drug. Participants-stratified analyses will be performed as required to account for these
anticipated differences.
Baseline data. Patient’s clinical featuresare recorded by participants on web-based CRF
(case report forms). Baseline data are demographic and clinical characteristics of patients, asso-
ciated risk factors for stroke and bleeding, laboratory routine data, clinical indication for treat-
ment, therapeutic range expected (in cases of treatment with VKA), use of concomitant drugs.
Serum creatinine levels are measured by local hospital laboratories, and creatinine clearance
(CrCl) is calculated by the Cockroft-Gault formula [14]. Renal failure was defined according to
National Kidney Foundation stratification [15].
Patients with non-valvular AF are stratified for stroke risk evaluation according to
CHADS2[16] and CHA2DS2VASc [17] scores while baseline bleeding risk is evaluated by using
HAS-BLED score [18]. In patients with venous thromboembolism, the assessment of VTE site
and presence of provoking factors is mandatory; presence of biochemical or molecular risk fac-
tors is optional.
Follow-up data. Participants are required to regularly follow-up enrolled patients at least
quarterly, by phone call or ambulatory visit. An ambulatory follow-up visit is mandatory at
least annually. Participants are required to provide detailed clinical reports of any relevant clin-
ical outcome occurring in enrolled patients. For patients on VKA, time spent in the therapeutic
range (TTR, computed according to the Rosendaal’s method [19]) is recorded every three
months for the first year, annually thereafter.
Events. Relevant clinical outcomes are major bleeding complications (using the classifica-
tion recommended by the International Society on Thrombosis and Haemostasis—[20]), any
thrombotic event, development of cancer, organ failure, and death. A major bleeding event is
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defined as a bleeding event that is accompanied by a decrease in hemoglobin (Hgb) 2 g/dL,
requiring transfusion with 2 units of packed red blood cells or occurring in a critical sites.
Clinically relevant non-major bleeding event are classified as bleeding that does not satisfy the
criteria for major bleeding but requiring hospital admission or a change in antithrombotic
therapy. Minor bleeding events are all bleeding satisfactorily managed in an ambulatory set-
ting. Diagnosis of stroke requires the abrupt onset of focal neurological symptoms lasting at
least 24 hours and supported by congruent ischemic lesions at CT or MRI scan. Systemic em-
bolism is defined by symptoms consistent with an acute loss of blood flow to a peripheral ar-
tery, which is supported by objective evidence of embolism. Acute MI is defined by thoracic
symptoms and troponin elevation 2 x ULN or significant Q waves. Pulmonary embolism is
diagnosed by detection of a new intraluminal filling on spiral CT scan, pulmonary angiogram
or ventilation/perfusion lung scan (VPLS). Deep vein thrombosis is diagnosed by thrombus de-
tection in a deep vein by abnormal compression ultrasound (CUS) or venography.
Statistical Analysis
Descriptive analysis was performed. Continuous variables are expressed median and interquar-
tile range (IQR) or as mean ±standard deviation(SD). Categorical variables are expressed as
frequencies and percentages. The SPSS software for Windows, version 19 (SPSS Inc, Chicago,
IL) was used for data processing.
Results
The inclusion of patients in the registry started in January 2012; at the time of the present anal-
ysis (December 2013) 90 Participants, equally distributed in Northern, Central and Southern
Italy, had enrolled 5252 patients. As shown in Table 1, males were slightly more represented
(53.7%) than females; median age was 74 years and almost one-fourth of all patients were> 80
year old (24.2%). NVAF was the most frequent indication for treatment present in almost two-
thirds of all patients (61.1%), followed by VTE (28.6%). VKAs were almost the only type of an-
ticoagulant drug used (Table 1).
Table 1. Patients enrolled in the START-Register, indication for anticoagulation and type of
treatment.
N. 5252
Males n (%) 2818(53.7)
Median age, y (interquartile range) 74 (64–80)
Patients aged > 75 years (%) 2302 (43.9)
Patients aged> 80 years 1268 (24.2)
Indication for Anticoagulant treatment n (%)
Non-valvular atrial ﬁbrillation 3209 (61.1)
Venous thrombembolism 1500 (28.6)
Heart prosthetic valves 223 (4.2)
Valvular atrial ﬁbrillation 104 (2.0)
Other 216 (4.1)
Type of treatment (%)
VKA 5130 (97.6)
DOAC 109 (2.1)
LMWH 13 (0.3)
VKA = vitamin k antagonist; DOAC = direct oral anticoagulant;
LMWH = light molecular weight heparin
doi:10.1371/journal.pone.0124719.t001
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The present analysis is focused on the baseline characteristics of the 3209 NVAF patients in-
cluded in the registry, listed in Table 2.
More than half of the patients were> 75 year old, and about one third was 80 years or
more. The distribution of patients stratified for stroke risk by using CHADS2 and CHA2DS2-
VASc score, and for bleeding risk by using HAS-BLED score is shown in Table 3.
Among the small group of 109 patients treated with DOAC, the median age was 76 years
[interquartile range (IQR) 70–81]; the mean CHADS2 and CHA2DS2VASc scores were
2.2 ± 1.3 and 3.1 ± 1.3, respectively; and the mean HAS-BLED score was 2.5± 0.9. The associa-
tion between VKA and an antiplatelet drug was present in 532 patients (16.6%), while other 50
anticoagulated patients were on double antiplatelet therapy (1.6%) (Table 2). The analysis of
renal function showed that 168 patients (5.3%) had severe renal failure (CrCl<30 ml/min).
Moderate renal failure (CrCl 30–59 ml/min) was found in 1265 patients (39.5%), and 329 pa-
tients in this group (10.3% of the whole cohort) had CrCl between 30 and 40 ml/min. Table 4
shows some clinical characteristics of NVAF patients enrolled in the study compared to those
of patients enrolled in the phase III trials with DOAC and those included in the observational
GARFIELD Registry [21].
Table 2. Clinical characteristics of NVAF patients included in the START-Register.
N. 3209
Median age, y (interquartile range) 76 (70,81)
Patients > 75 y (%) 1691 (52.7)
Patients 60–69 y 546 (17.0)
Patients 70–79 y 1373 (42.8)
Patients 80–89 y 1002 (31.2)
Patients  90 y 55 (1.7)
Males (%) 1770 (55.2)
Chronic NVAF (%) 1691 (52.7)
Type of treatment
Warfarin 3070 (95.7)
Acenocoumarol 38 (1.2)
Dabigatran- Rivaroxaban 101 (3.1)
Past medical history (%)
Heart failure 463 (15.0)
Hypertension 2673 (84.9)
Diabetes 639 (20.6)
Coronary Artery Disease 616 (19.9)
Peripheral Artery disease 169 (5.5)
Previous stroke/TIA 448 (14.6)
Previous major bleeding 64 (2.0)
Other characteristics at inclusion (%)
CHADS2 score (mean±SD) 2.1±1.1
CHA2DS2VASc score (mean±SD) 3.0 ± 1.3
HAS-BLED score (mean±SD) 2.5± 1.0
Active cancer 76 (2.5)
Creatinine clearance <30 ml/min 168 (5.3)
Antiplatelet drugs + VKAs 532 (16.6)
Dual antiplatelet drugs + VKAs 50 (1.6)
VKA = vitamin k antagonist; TIA = Transient ischemic attack
doi:10.1371/journal.pone.0124719.t002
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Finally, we estimated the number of NVAF patients who would have been compliant with
the rules recently issued by the Italian Regulatory Drug Agency (AIFA) to receive from the Na-
tional Health System complete reimbursement of treatment with one of the marketed DOAC.
For VKA-naïve patients (as were the patients included in the registry), there were two criteria
established by the Agency: a) the concurrent presence of two clinical characteristics: a
CHA2DS2VASc score above a specific value that was different for the various drugs (see
Table 5) and a HAS-BLED score> 3 (for all the drugs); or b) the impossibility of performing
the VKA-therapy due to the presence of objective difficulties to comply with the need for the
periodic laboratory controls (a condition that was not relevant in our series of patients). After
exclusion of patients with severe renal insufficiency (following the criterion established by drug
producers) the number of patients who would have been compliant with the two a) criteria was
calculated. In line with the criterion of a HAS-BLED score> 3, which was the most restrictive,
only about 15% of patients qualified for being treated with DOAC.
Table 3. Clinical characteristics of AF patients in relation to stroke and bleeding risk stratification models.
Score CHADS2 n(%) CHA2DS2VASc n(%) HAS-BLED* n (%)
0 196 (6.6) 59 (2.0) 77 (2.5)
1 842 (28.2) 267 (9.0) 362 (11.9)
2 1108 (37.1) 729 (24.6) 1024 (33.6)
3 496 (16.6) 981 (33.1) 1132 (37.1)
4 274(9.2) 532 (17.9) 409 (13.4)
5 63 (2.1) 301 (10.1) 45 (1.5)
6 5 (0.2) 84 (2.8) 1 (0.0)
7 14 (0.5)
8 1 (0.0)
9 /
*all patient were naïve, no time in therapeutic range
doi:10.1371/journal.pone.0124719.t003
Table 4. Some characteristics of NVAF patients enrolled in START-Register, compared to those in the GARFIELD Registry and in randomized tri-
als on DOAC.
START Garﬁeld [19] RE-LY [3] Rocket-AF [4] Aristotle [5] Engage AF [6]
Age yrs 74.6±9.6 70±11 72±9 73 (65,78) 70 (63,76) 72 (64,78)
CrCl ml/min %
30–59 39.7 11.4
30–50 23.9 19.3 20.8 15.1 19.3
< 30 5.3 2.0 Excluded Excluded 1.5* Excluded
< 15 0.02
BMI 28.3±5.1 28±5 82.6 Kg ±19.9 28 (25,32) 82 Kg (70–95) NA
History of ACS % 20 10 17 17 15 NA
Diabetes % 21 22 23 40 19.4 36.1
CHADS2 score 2.1±1.1 1.9±1.2 2.1±1.1 3.5±0.9 2.1±1.1 2.8±1.0
DOAC = direct oral anticoagulant
CrCl = creatinine clearance
Data are expressed as mean ± SD, or median (IQR), or %; NA = not available
* = patients with CrCl<25 ml/min were excluded
doi:10.1371/journal.pone.0124719.t004
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Discussion
This is the first paper presenting the Start-Register, an ongoing, collaborative, prospective, ob-
servational Register aimed at recording the clinical history of patients starting anticoagulant
treatment, whatever the drug and dosage used and whatever the indication to treatment. Data
reported in this paper describe the baseline characteristics of patients included after the first
two years of activity of the Register, in particular focusing on those with NVAF who in the
large majority received warfarin. In fact, only a small group of included patients were treated
with DOAC. The DOAC currently available and reimbursable by the National Health System
for treatment of NVAF (dabigatran, rivaroxaban, apixaban) have been marketed in Italy only
during the last few months; furthermore the Italian Regulatory Drug Agency (AIFA) has estab-
lished strict regulations to allow the prescription of a DOAC limiting in this way their use.
Since the Participants in the Registry are equally distributed across Italy, the present inception-
cohort can be considered representative of patients starting anticoagulation throughout Italy.
Patients were relatively old, with just under half of them being> 75 years old at inclusion. Non
valvular atrial fibrillation was the most frequent indication for anticoagulation (61.1%), fol-
lowed by VTE (28.6%).
The analysis of NVAF subjects shows that the mean age of patients enrolled was slightly higher
than that observed in the trials on DOAC and in the GARFIELD Registry [21]. One third of our
patients were> 80 years old at inclusion; this confirms the advanced age of patients treated for
this indication, this subpopulation is not sufficiently represented in phase III trials on DOAC
(7–9,11). Other clinical characteristics of our cohort are comparable to those observed in patients
enrolled in observational registries [21–23] Instead, our NVAF cohort shows a particularly high
prevalence of moderate renal failure (CrCl 30–59ml/min). As a matter of fact, moderate renal fail-
ure is present in about 40% of patients enrolled in the Registry compared with only 11% in GAR-
FIELD’s cohort and 15–20% in trials with DOAC. In addition, the percentage of patients with
severe renal failure, a group of patients excluded from the above trials, is higher than in the GAR-
FIELD Registry, reaching 5% of our NVAF population. The presence of renal failure appears to be
particularly important in the START Registry NVAF population. This finding can be in part ex-
plained by the older age of our population, that is represented for 45% by patients with75 years.
The cohort of patients with moderate renal failure is of particular clinical interest because patients
are exposed to a rapid worsening of the renal function in case of intercurrent diseases, such as in-
fections or heart failure. If treated with a DOAC this group of patients should be carefully moni-
tored. DOAC are in fact mainly cleared via the kidneys—though with important differences
between the available drugs—and tend to accumulate in case of kidney failure, with a subsequent
Table 5. Number of anticoagulation-naive patients with NVAF who at the moment of inclusion in the START-Register would have been compliant
with the lower limit of creatinine clearance declared by the drug companies and with the criteria established from the Italian Regulatory Agency
(AIFA), in order to be potentially treated with DOA. The criterion regarding the individual difficulties in performing the laboratory control of INR, as well as
the percentage of time in range (all the START-Register patients were VKA-naive at inclusion) have not been taken into account for this evaluation.
Dabigatran* Rivaroxaban** Apixaban¶
patients eligible 3041 patients eligible 3195 patients eligible 3195
CHA2DS2-VASc  1 = 2746/3041 (90.3) > 3 = 932/3195 (29.2) > 2 = 1913/3195 (59.9%)
HAS-BLED > 3 = 455/3041 (15.0) > 3 = 455/3195 (14.2%) > 3 = 455/3195 (14.2%)
CrCl = creatinine clearance
*after exclusion of 168 patients with CrCl< 30 ml/min
**after exclusion of 14 patients with CrCl< 15 ml/min
¶after exclusion of 14 patients with CrCl< 15 ml/min
doi:10.1371/journal.pone.0124719.t005
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increase in bleeding risk. In our cohort moderate renal failure is found in about 40% of patients,
and about 10% have CrCl< 40 ml/min. It is worth noting that about 10% of patients treated with
DOAC in our cohort are in this high risk group.
We are aware that our study has limitation. The participants to the Registry are mainly
Anticoagulation Clinics and cardiologists, instead neurologists and general practitioners are
less represented. However, consecutive patients enrolment is mandatory so limiting the selec-
tion of patients. In addition, participants in the Registry are geographically widely distributed
across Italy, involving Centres of some small and main Italian cities.
Finally, it should be noted that, in accordance with the regulations established by the Italian
Regulatory Drug Agency (AIFA), only a small portion (approximately 15%) of NVAF patients in-
cluded in the Registry could have received the treatment with one of the available DOAC and re-
imbursed by the Italian National Health System. In fact, only a small portion of VKA-naïve
NVAF patients proved to be compliant with the AIFA’s criteria for treatment reimbursement in.
These criteria have been defined on the basis of the characteristics of patients enrolled in DOACs
phase 3 trials, and not on the basis of cost-effectiveness analysis. However, this choice is question-
able for several aspects. One of these is the indication to use DOAC in patients with a HAS-BLED
score3. These drugs have shown a safety performance at least similar to that of VKA, and in
some cases even better, without any specific relationship with the HAS-BLED. Furthermore, two
items that concur in the scoring, or are not available in VKA-naïve subjects (labile-INR, 1 point),
or are conditions that may put at risk the use of DOAC (renal or liver function impairment, 1
point each). As regards the CHA2DS2VASc score evaluation, it is singular that the minimal level
accepted for reimbursement differs so widely across the three available drugs. Unless the Agency
is aware of results not available in the published trials, it is difficult to understand why patients
should have a score of 4 or more to receive reimbursement with rivaroxaban, of 3 or more with
apixaban, while a score of 1 is sufficient to be treated with dabigatran. For the above reasons, and
for the need of fair and objective comparison of performances of different DOAC in a context of
real life, we hope that these regulations can soon be changed by our Agency.
In conclusion, the analysis of baseline characteristics of the inception-cohort anticoagulated
patients included in the START Register shows that almost two-third of patients started chron-
ic anticoagulant treatment because of NVAF, and one-third of them is> 80 years at inclusion.
The prevalence of renal failure is especially high in our NVAF population, since about 40% of
patients have moderate and> 5% severe renal failure, the latter being an exclusion criterion in
almost all the trials on DOAC. The START Register is now prospectively including non-
selected new anticoagulated patients and collecting all the clinical data regarding their initial
conditions and follow-up. The clinical use of DOAC started very recently in our country and
the Registry will allow the clinical history of patients treated with conventional or newly pro-
posed anticoagulant agents to be compared.
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